Yu Tze Ng
Neurology with Special Qualifications in Child Neurology · Overland Park, KSNPI 1215041942
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $56,132 of the $92,338 with a category attached, or 60.8%. 24 manufacturers reported payments, led by Greenwich Biosciences, Inc. at 32.4% of the total. Reporting peaked in 2019 at $70,124 and has fallen 99.4% since, to $423 in 2025.
Across 202 payments — averaging $457.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Greenwich Biosciences, Inc.$30K
- Eisai Inc.$22K
- Aquestive Therapeutics, Inc.$20K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- SK Life Science, Inc.$6K
- Livanova USA, Inc.$2K
- plus $3K from 18 others
Across 18 payments — averaging $15,968 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GW Research Limited$156K
- UCB Biosciences Inc.$112K
- Eisai Inc.$10K
- Zogenix Inc.$4K
- UCB SA$3K
- UCB, Inc.$2K
What the payments were for
- Consulting fees$16,18618%
- Speaking & faculty fees$56,13261%
- Travel & lodging$11,78913%
- Food & beverage$8,2329%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Greenwich Biosciences, Inc. | 36 | $29,955 |
| Eisai Inc. | 33 | $22,441 |
| Aquestive Therapeutics, Inc. | 39 | $19,976 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $9,330 |
| SK Life Science, Inc. | 15 | $5,943 |
| Livanova USA, Inc. | 18 | $1,706 |
| Monteris Medical Corporation | 7 | $863 |
| UCB, Inc. | 10 | $627 |
| Immedica Pharma US, Inc. | 3 | $351 |
| Jazz Pharmaceuticals Inc. | 9 | $230 |
| Vanda Pharmaceuticals Inc. | 3 | $164 |
| Sunovion Pharmaceuticals Inc. | 1 | $125 |
| Biocodex, Inc. | 1 | $125 |
| Mallinckrodt Hospital Products Inc. | 1 | $123 |
| Catalyst Pharmaceuticals, Inc. | 1 | $118 |
| Neurelis, Inc. | 2 | $59 |
| Johnson & Johnson | 2 | $35 |
| Noven Therapeutics, LLC | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| AstraZeneca | 1 | $21 |
| NS Pharma, Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$29,771
- Fycompa$22,081
- SYMPAZAN$18,964
- XCOPRI$5,346
- VNS Therapy$1,128
- Neuroblate$677
- ZTALMY$351
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$260
- Briviact$161
- APTIOM$125
- DIACOMIT$125
- ACTHAR$123
- VNS - Sentiva$106
- Fintepla$102
How this compares
Too few neurology with special qualifications in child neurology providers in Kansasto place this figure against a meaningful peer group, so we don't.
Other neurology with special qualifications in child neurology in Overland Park
- Britton ZuccarelliSalina$314K
- Bassem El-NabboutWichita$12K
- Jean-Baptiste le PichonTopeka$10K
- Subhash ShahWichita$2K
- Aruna Deepthi Markonda PatnaikWichita$1K
- Gina JonesTopeka$40
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.